BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 27819858)

  • 1. 18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods.
    Mena E; Sheikhbahaei S; Taghipour M; Jha AK; Vicente E; Xiao J; Subramaniam RM
    Clin Nucl Med; 2017 Jan; 42(1):e16-e21. PubMed ID: 27819858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.
    Chirindel A; Alluri KC; Chaudhry MA; Wahl RL; Pawlik TM; Herman JM; Subramaniam RM
    AJR Am J Roentgenol; 2015 May; 204(5):1093-9. PubMed ID: 25905947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma.
    Mena E; Taghipour M; Sheikhbahaei S; Jha AK; Rahmim A; Solnes L; Subramaniam RM
    Clin Nucl Med; 2017 May; 42(5):e227-e234. PubMed ID: 28195905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
    Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
    PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.
    Nakajo M; Nakajo M; Jinguji M; Fukukura Y; Nakabeppu Y; Tani A; Yoshiura T
    Br J Radiol; 2015; 88(1055):20150552. PubMed ID: 26337605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.
    Kawada N; Uehara H; Hosoki T; Takami M; Shiroeda H; Arisawa T; Tomita Y
    Pancreas; 2015 May; 44(4):655-9. PubMed ID: 25815646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical value of texture analysis of dual-time-point
    Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT.
    Watabe T; Tatsumi M; Watabe H; Isohashi K; Kato H; Yanagawa M; Shimosegawa E; Hatazawa J
    Ann Nucl Med; 2012 Apr; 26(3):222-7. PubMed ID: 22187313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
    Sakane M; Tatsumi M; Hori M; Onishi H; Tsuboyama T; Nakamoto A; Ota T; Eguchi H; Wakasa K; Hatazawa J; Tomiyama N
    Eur J Radiol; 2017 Sep; 94():64-69. PubMed ID: 28712692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma.
    Hyun SH; Kim HS; Choi SH; Choi DW; Lee JK; Lee KH; Park JO; Lee KH; Kim BT; Choi JY
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1461-8. PubMed ID: 26872788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer.
    Garcia-Vicente AM; Molina D; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Bueno G; Tello-Galán MJ; Soriano-Castrejón Á
    Ann Nucl Med; 2017 Dec; 31(10):726-735. PubMed ID: 28887761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of volumetric whole-body
    Araç E; Can C; Kömek H
    Hell J Nucl Med; 2020; 23(1):40-47. PubMed ID: 32361716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
    Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
    J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods.
    Shah B; Srivastava N; Hirsch AE; Mercier G; Subramaniam RM
    Ann Nucl Med; 2012 Nov; 26(9):707-14. PubMed ID: 22797818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity index evaluated by slope of linear regression on
    Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1995-2003. PubMed ID: 28634684
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of Intratumoral Metabolic Heterogeneity and Quantitative
    Pinho DF; King B; Xi Y; Albuquerque K; Lea J; Subramaniam RM
    AJR Am J Roentgenol; 2020 Apr; 214(4):908-916. PubMed ID: 32069078
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
    Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
    Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.